For this annual special report, which is in its 31st year of publication, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
While the world’s leading prescription drug Humira still accounts for the majority of AbbVie’s revenue, plenty else is bubbling up at the almost-five-year-old company.
Amgen is featuring an unprecedented collection of new product offerings, including the first-ever biosimilar cancer treatment to receive U.S. marketing clearance.
Although patent expirations continue to depress revenue, AstraZeneca executives believe in the pipeline.
For Bayer, the acquisition of Monsanto is intended to build its Crop Science division; meanwhile two significant approvals and two new hires enhance progress in oncology.
After years of hope and hype, Bristol-Myers Squibb’s centerpiece immuno-oncologic Opdivo is delivering the dollars.
With sales of Harvoni and Sovaldi falling off, Gilead welcomed two new blockbusters to the company’s portfolio in 2016.
Management set out a series of new priorities to 2020 to improve innovation, performance and trust in GlaxoSmithKline.
With proven worldwide commercial capabilities and a robust product pipeline, Johnson & Johnson is firmly positioned to continue generating strong, long-term, sustainable growth.
New CEO David Ricks took over Lilly as the company continues to climb out of its post-Cymbalta/Zyprexa rut.
Easily the fastest grower in Merck’s portfolio, the oncology drug Keytruda is piling up dollars and indications at an impressive rate.
2017 is serving as another challenging year for Novartis as the company continues to work through the Gleevec/Glivec patent expirations that began in 2016, but management is confident that a new phase of growth will start in 2018.
Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.
Pfizer is overcoming patent expirations by developing a steady new stream of products.
Roche’s Pharmaceuticals and Diagnostics Divisions continue to generate strong performances significantly driven by new product launches, including four new oncology treatments and the company’s first cancer immunotherapy medicine.
Sanofi executives continue to have faith in strategic plans to get the company to new heights despite continued impact from patent expirations.
Now on its seventh CEO in the last 10 years and in danger of losing its most valuable branded product, Teva is searching for answers.
HBA’s 2017 Annual Conference will be held in Philadelphia on Nov. 6-8, 2017.